Point Biopharma Inc. entered into a non-binding letter of intent to acquire Therapeutics Acquisition Corp. (NasdaqCM:RACA) from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction on February 9, 2021. Point Biopharma Inc. entered into definitive business combination agreement to acquire Therapeutics Acquisition Corp. in a reverse merger transaction for approximately $780 million on March 15, 2021. A group of top-tier investors has committed to participate in the transaction through a common stock PIPE of approximately $165 million at $10.00 per share. All of the shares of current POINT shareholders and all of the vested equity awards of holders will be converted into shares or equivalent awards of the Combined Company at an implied POINT equity value of $585 million. Current Therapeutics Acquisition shareholders are converting their shares of Class A common stock into common stock of the Combined Company on a one for one basis. Upon completion, existing Point shareholders will have 63% ownership in the combined company. The Combined Company common stock is expected to trade on the Nasdaq Capital Market upon closing, under the ticker symbol “PNT”. Assuming a share price of $10.00 per share, the Combined Company is expected to have an initial equity value of approximately $924 million. POINT Biopharma is expected to receive approximately $300 million in proceeds through the business combination, including a $165 million fully-committed PIPE led by RA Capital Management and other investors. Upon closing of the business combination, Therapeutics Acquisition will be renamed POINT Biopharma Global Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol “PNT”. POINT's management team will lead the Combined Company post-closing, and Joe McCann will serve as the Chief Executive Officer of the Combined Company. David Lubner, one of the directors of Therapeutics Acquisition, will be joining the board of directors of the Combined Entity.

The obligations of the Parties to consummate the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by the Party for whose benefit such condition exists of the following conditions: (a) the applicable waiting period under the HSR Act relating to the transactions contemplated by this Agreement shall have expired or been terminated; (b) no Order or Law issued by any court of competent jurisdiction or other Governmental Entity or other legal restraint or prohibition preventing the consummation of the transactions contemplated by this Agreement shall be pending or in effect; (c) the Registration Statement / Proxy Statement shall have become effective; (d) RACA's initial listing application with Nasdaq in connection with the transactions contemplated by this Agreement shall have been approved and, immediately following the Effective Time, RACA shall satisfy any applicable initial and continuing listing requirements of Nasdaq, and RACA shall not have received any notice of non- compliance therewith that has not been cured or would not be cured at or immediately following the Effective Time, and the RACA Shares to be issued pursuant to the Merger and the transactions contemplated by this Agreement shall have been approved for listing on Nasdaq; (e) after giving effect to the transactions contemplated hereby, RACA shall have at least $5,000,001 of net tangible assets immediately after the Effective Time; (f) the Registration and Stockholder Rights Agreement duly executed by the stockholders of the Company set forth therein. The deal is subject to approval of both Therapeutics Acquisition's and POINT's shareholders. The boards of directors of POINT have approved the proposed transaction. The boards of directors of Therapeutics Acquisition have unanimously approved the transactions. On June 9, 2021, Therapeutics Acquisition announcing that its registration statement on Form S-4 (as amended, the “Registration Statement”) has been declared effective by the SEC. The transaction was approved at a special meeting of stockholders of Therapeutics Acquisition Corp. held on June 29, 2021. The transaction is expected to be completed by mid-year 2021. As of April 29, 2021, the Business Combination is expected to close in May 2021. As of June 9, 2021, the transaction is expected to be completed by September 15, 2021.

Perella Weinberg Partners LP is acting as lead financial advisor whereas Jay Jay Knight, Jonathan Stanley, Susan Sidwell, Tatjana Paterno, Andrew Hard, Lauren Brown, James Litzow, Lora Wuerdeman, Mary Lindsey Hannahan, Dixon Babb, Curtis Capeling, Shelley Thomas, Shu Chen, Caitlin Wilkinson, Clint Hermes, Amy Morgan, Angelique Salib, Bryan Metcalf , Doug Dahl, Curtis Fisher, Brett Good, Lymari Cromwell and Lucas Smith of Bass, Berry & Sims PLC acting as lead legal counsels to POINT. Jefferies LLC is acting as lead financial and Jocelyn Arel, Dan Espinoza, Blake Liggio & Laurie Burlingame of Goodwin Procter LLP acting as lead legal counsels to Therapeutics Acquisition. Continental Stock Transfer & Trust Company acted as transfer agent Therapeutics Acquisition. Morrow Sodali LLC acted as proxy solicitor to Therapeutics Acquisition and Therapeutics Acquisition has agreed to pay $30,000.

Point Biopharma Inc. completed the acquisition of Therapeutics Acquisition Corp. (NasdaqCM:RACA) in a reverse merger transaction on June 30, 2021.